Goodwin advised Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) on its definitive agreement with Catalent, Inc., for Catalent to acquire all of the outstanding shares of Juniper at…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
